Processa Pharmaceuticals (PCSA) Return on Capital Employed (2013 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Return on Capital Employed came in at 345.64% in Q1 2026, up 9612.0% YoY from 3.56% in Q1 2025, and down 34.98% on a QoQ basis from 256.07% in Q4 2025.
Processa Pharmaceuticals (PCSA) Return on Capital Employed (2013 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 14 years of Return on Capital Employed data on file, last reported at 345.64% in Q1 2026.
- Quarterly Return on Capital Employed rose 9612.0% year-over-year to 345.64% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 345.64% (up 9612.0% YoY) and the FY2025 annual result came in at 425.81%, down 2077.0% from the prior year.
- Return on Capital Employed eased to 345.64% in Q1 2026, from 256.07% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 54.14% in Q1 2022 to a low of 472.02% in Q4 2024.
- A 5-year average of 236.7% and a median of 233.28% in 2024 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 21596 bps in 2025, down 29353 bps in 2025.
- Tracing PCSA's Return on Capital Employed over 5 years: stood at 218.22% in 2022, then climbed by 15 bps to 184.67% in 2023, then plunged by 156 bps to 472.02% in 2024, then soared by 46 bps to 256.07% in 2025, then tumbled by 35 bps to 345.64% in 2026.
- The last three Return on Capital Employed figures came in at 345.64% (Q1 2026), 256.07% (Q4 2025), and 212.34% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | -1,415.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -345.64% |
| Dec 31, 2025 | -256.07% |
| Sep 30, 2025 | -212.34% |
| Jun 30, 2025 | -293.08% |
| Mar 31, 2025 | -441.76% |
| Dec 31, 2024 | -472.02% |
| Sep 30, 2024 | -233.28% |
| Jun 30, 2024 | -145.80% |
| Mar 31, 2024 | -148.23% |
| Dec 31, 2023 | -184.67% |
| Sep 30, 2023 | -267.00% |
| Jun 30, 2023 | -248.51% |
| Mar 31, 2023 | -339.52% |
| Dec 31, 2022 | -218.22% |
| Sep 30, 2022 | -94.13% |
| Jun 30, 2022 | -69.51% |
| Mar 31, 2022 | -54.14% |
| Dec 31, 2021 | -45.32% |
| Sep 30, 2021 | -66.39% |
| Jun 30, 2021 | -61.14% |